AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03697174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 200 ppb ozone group
Description: The exposure group will be exposed to 200 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
Study NCT02406560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: fasted
Study NCT02406560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: high fat meal
Study NCT02406560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Study NCT02674880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMW-HA
Description: Aerolized administration b.i.d.
Study NCT02674880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard therapy
Study NCT00645762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RS-Series Rhinosinusitis Treatment System
Description: Single arm
Study NCT00645762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FinESS Balloon
Study NCT01978730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose group of SaiLuoTong capsule
Description: high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
Study NCT01978730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose group of SaiLuoTong
Description: low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
Study NCT01978730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: the control group
Description: The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
Study NCT03113877 — intervention group
Intervention type: OTHER
Intervention: Autonomic Dysfunction Testing
Description: The participants with CdLS will complete the COMPASS-31 survey and will complete standard clinical testing for autonomic dysfunction including an autonomic reflex screen (tilt table and quantitative sudomotor axon reflex testing) and thermoregulatory sweat test (TST).
Study NCT04238754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex 100 mg/mL Oral Solution
Study NCT04238754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidiolex
Description: Epidiolex 100 mg/mL Oral Solution
Study NCT04238754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cherry syrup oral solution
Study NCT04238754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cherry syrup oral solution
Study NCT01259791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individual-specific statin causing myopathy
Description: Individual-specific statin causing myopathy vs. placebo
Study NCT03697174 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 0 ppb ozone group
Description: The control group will be exposed to 0 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
Study NCT01732094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
Study NCT01732094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 150μg
Description: Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
Study NCT01732094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hpHMG
Description: hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
Study NCT02868814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Release Tablets
Study NCT02868814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00831649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Study NCT03106766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acne cream 2X
Description: Twice daily application of facial acne cream 2X after facial cleansing
Study NCT03106766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acne cream 1X
Description: Twice daily application of facial acne cream 1X after facial cleansing
Study NCT00628238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide and Rituximab
Description: Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
Study NCT00979797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based interventions to promote maternal and child health
Description: Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
Study NCT01245517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Dietary Phosphorus Education Program
Study NCT03004573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological detailed tests with focus on social cognition
Description: MATTIS, MOCA, BREF, Light points test, PDQ39
Study NCT02383030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
Study NCT02606942 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, physical exam, US of the knee
Description: Function and pain questioners, physical findings and sonographic study of the knee joint
Study NCT02048982 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Guideline
Description: Physicians will receive information on the Choosing Wisely Guideline
Study NCT02048982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline
Description: Physicians will receive information on the Choosing Wisely Guideline
Study NCT02048982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline
Description: Physicians will receive information on the Choosing Wisely Guideline
Study NCT01259791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03506763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral + Placebo Oral
Description: Placebo Oral + Placebo Oral
Study NCT03506763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac oral + Placebo Oral
Description: Diclofenac oral + Placebo Oral
Study NCT03506763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac oral + scopolamina oral
Description: Diclofenac oral + scopolamina oral
Study NCT04985019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Prepectoral)
Description: Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
Study NCT04985019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm II (Subpectoral)
Description: Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
Study NCT03547622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAT taper with galantamine
Description: Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
Study NCT02904343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: domestic hemodialysis machine
Description: WEGO, DBB-27C
Study NCT02904343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imported hemodialysis machine
Description: Fresenius, 4008s
Study NCT02048982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cost
Description: Physicians will receive cost information.
Study NCT03547622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAT taper with placebo
Description: Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
Study NCT00520130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
Study NCT00520130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
Study NCT00520130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic stem cell transplant (ASCT)
Description: Allogenic stem cell transplant
Study NCT06038552 — intervention group
Intervention type: DRUG
Intervention: imatinib (IM)
Description: Patients with GIST liver metastases were administered an initial IM dose of 400 mg daily, while those with KIT exon 9 mutations received 600-800 mg daily. All patients continued IM indefinitely unless progression or intolerable adverse reactions.
Study NCT06038552 — intervention group
Intervention type: PROCEDURE
Intervention: hepatic resection (HR)
Description: HR The determination of the surgical modality was established subsequent to comprehensive consultations tailored to each patient within the Department of Liver Surgery. The surgical strategy was established in consideration of factors such as the residual liver volume, tumour positioning, and the surgeon's personal preference. Employing an intraoperative ultrasonographic to enhance the precision of operative assessment.
Study NCT06038552 — intervention group
Intervention type: PROCEDURE
Intervention: radiofrequency ablation (RFA)
Description: RFA RFA was executed utilizing the commercially accessible Cool-tip™ RFA system or the RF 2000 system. The electrode was percutaneously inserted through a guide needle under real-time ultrasound guidance.The primary objective of the RFA procedures encompassed the complete elimination of the tumour entity, with a prescribed ablative margin of 0.5 cm meticulously factored in.
Study NCT02048982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Victim
Description: Physicians will receive information on an identifiable victim.
Study NCT02048982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Victim
Description: Physicians will receive information on an identifiable victim.
Study NCT01425216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
Study NCT01452542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat, common blend proposed commercial formulation
Description: All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.
Study NCT01452542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat, Phase 3 capsule formulation
Description: All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
Study NCT06038552 — intervention group
Intervention type: PROCEDURE
Intervention: transarterial chemoembolization (TACE)
Description: TACE Under a comprehensive assessment of the hepatic arterial blood supply, a selective catheter was introduced into the segmental or subsegmental arteries that supplied the tumour. The regimen of hepatic arterial infusion chemotherapy included infusion of carboplatin 300 mg, a mixture of 50 mg of epirubicin and 8 mg of mitomycin C, intimately blended with 5 mL of lipiodol. Embolization was finally performed with either absorbable gelatin sponge particles or polyvinyl alcohol particles .
Study NCT04304703 — intervention group
Intervention type: DEVICE
Intervention: WHOOP strap 3.0
Description: WHOOP strap 3.0, a photodiode-based device that tracks sleep, resting heart rate, and heart rate variability.
Study NCT01449084 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate stent removal
Description: The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE
Study NCT01449084 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Leaving the stent in place
Description: The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE
Study NCT01843231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: g-CathTM EZ Suture Anchor Delivery Catheter
Description: Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
Study NCT01843231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise Control Group
Description: Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
Study NCT01459029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D-serine
Description: Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
Study NCT01459029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-serine
Description: Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
Study NCT02981576 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Mesenchymal Stem Cells
Description: Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.
Study NCT02327715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery
Study NCT02622334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.
Study NCT02622334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo formulation will be administered in Part A.
Study NCT02622334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
Study NCT01533129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testogel 50 mg transdermal gel
Description: 50mg testosterone gel implementation on every night
Study NCT01533129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 250mg injection
Description: The testosterone 250mg ester IM injections performed in three weeks.
Study NCT03176342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patch test
Description: Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
Study NCT03874481 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: follow up regularly for MACE
Study NCT02262312 — intervention group
Intervention type: OTHER
Intervention: Transient elastography
Description: All patients will have a transient elastography performed as a measure of liver stiffness.
Study NCT02319382 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET with the tracer 18F-DPA-714
Study NCT02319382 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET with the tracer 11C-PE2I
Study NCT02319382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic field
Study NCT01428245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
Study NCT01428245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrace (estrogen)
Description: oral estrace, 0.5-1 mg once a day for seven days
Study NCT00759096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESTOR IOL Model SA60D3
Description: Implanted into the study eye following cataract extraction surgery
Study NCT02115477 — intervention group
Intervention type: PROCEDURE
Intervention: Lymphadenectomy
Description: Pelvic and/or paraaortic lymphadenectomy
Study NCT01529996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Dye Laser/YAG laser
Description: This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
Study NCT01529996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse Dye Laser/YAG laser
Description: This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
Study NCT01911338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Time Feedback
Description: Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
Study NCT01221909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
Study NCT01221909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 5cc saline solution
Study NCT01911338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Learning Method
Description: Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
Study NCT02981641 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Description: Total dose: 18\~22 Gy; Single dose: 18\~22 Gy; Frequency: 1
Study NCT02981641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy
Description: Sequential chemotherapy
Study NCT02981641 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Three dimensional conformal radiation therapy (3D-CRT)
Description: Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30
Study NCT02981641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
Study NCT01935804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg/daily for 12 months
Study NCT01935804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 850 mg/daily for 12 months
Study NCT03731143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of self retaining bicanalicular stent
Description: The pigtail probe was passed through the canalicular system from the normal punctum to the occluded aspect. When the tip of the pigtail probe was positioned near the occluded punctal area, the surgeon pushed the area to be tented with the pigtail probe. After they advanced the pigtail probe back and forth several times until they could locate the correct position of the occluded punctum, the authors incised the tented area with a scalpel No. 11 to make a new punctal opening.~To ensure punctal and canalicular patency, syringing was repeated through the perforated punctum. To prevent re-occlusion of punctal opening, a self retaining bicanalicular tube (FCI®; Paris, France) was inserted through the normal and perforated puncti
Study NCT02562469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTIVATE
Description: A home-based computerized brain training intervention for youth.